Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Drops By 48.1%

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large drop in short interest in May. As of May 15th, there was short interest totaling 562,363 shares, a drop of 48.1% from the April 30th total of 1,083,465 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average trading volume of 643,391 shares, the days-to-cover ratio is currently 0.9 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Liminatus Pharma currently has an average rating of “Sell”.

Liminatus Pharma Stock Up 11.0%

Shares of Liminatus Pharma stock traded up $0.02 during trading on Monday, reaching $0.18. The company’s stock had a trading volume of 6,452,543 shares, compared to its average volume of 10,947,683. The company has a market cap of $8.17 million and a price-to-earnings ratio of -0.42. Liminatus Pharma has a 1-year low of $0.13 and a 1-year high of $33.66. The company has a 50-day simple moving average of $0.19 and a two-hundred day simple moving average of $0.53.

Liminatus Pharma (NASDAQ:LIMN) last issued its earnings results on Friday, May 15th. The company reported ($0.03) earnings per share (EPS) for the quarter.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.